“`html
STOCKHOLM, July 31, 2025 /PRNewswire/ — BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) is riding high on the success of Leqembi, its Alzheimer’s drug developed in partnership with Eisai. Eisai, in conjunction with Biogen’s Q2 report, released preliminary global revenue figures for Leqembi, showcasing a robust JPY 23.1 billion in sales for the second quarter of 2025.
This translates to a royalty windfall for BioArctic, reaching SEK 162.5 million, marking an impressive 280% jump compared to royalties earned in Q2 2024. The market is clearly responding to Leqembi’s potential impact on treating early Alzheimer’s disease, a space long awaiting effective therapies.
However, digging into the details, the figures include a one-time stockpiling effect in China, estimated at around JPY 5.3 billion, driven by concerns over potential tariffs. Excluding this factor, global sales still hit a respectable JPY 17.8 billion, generating royalty revenue of approximately SEK 125 million for BioArctic. This suggests underlying demand remains strong even without the artificial boost from stockpiling.
BioArctic is scheduled to release its full Q2 2025 report on August 28 at 08:00 a.m. CET, where investors will be keen to analyze the sustainable growth rate of Leqembi and its long-term market potential.
This information constitutes inside information that BioArctic AB (publ) is required to disclose under the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, on July 31, 2025, at 12:00 CET.
For further information, please contact:
Oskar Bosson, VP Communications and Investor Relations
E-mail: [email protected]
Telephone: +46 704 107 180
About lecanemab (Leqembi®)
Lecanemab is the fruit of a strategic research alliance between BioArctic and Eisai. It’s a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody that zeroes in on aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ). Lecanemab has secured regulatory approval in 46 countries, including the U.S., Japan, China, and the European Union, marking a significant step forward in treating Alzheimer’s disease (AD) in patients with Mild Cognitive Impairment (MCI) or mild dementia (collectively, early AD). It’s also under regulatory review in 10 additional countries, signaling its expanding global reach.
Since July 2020, Eisai’s Phase 3 clinical study (AHEAD 3-45) with lecanemab has been underway, targeting individuals with preclinical AD, who are clinically normal but exhibit intermediate or elevated levels of amyloid in their brains. The study reached full enrollment in October 2024. AHEAD 3-45 is a four-year public-private partnership between Eisai, Biogen, and the Alzheimer’s Clinical Trial Consortium. This consortium provides the infrastructure for academic clinical trials in AD and related dementias in the U.S., with funding from the National Institute on Aging, a division of the National Institutes of Health. Since January 2022, the Tau NexGen clinical study for Dominantly Inherited AD (DIAD), conducted by the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) at Washington University School of Medicine in St. Louis, has incorporated lecanemab as its core anti-amyloid therapy.
About the collaboration between BioArctic and Eisai
BioArctic and Eisai have maintained a long-standing collaboration since 2005, focused on the development and commercialization of Alzheimer’s disease treatments. Key agreements include the Development and Commercialization Agreement for the lecanemab antibody (signed in 2007) and the Development and Commercialization agreement for the antibody Leqembi back-up for Alzheimer’s disease (signed in 2015). In 2014, Eisai and Biogen forged a joint development and commercialization agreement for lecanemab. Eisai takes the lead in clinical development, market approval applications, and commercialization for Alzheimer’s disease products. BioArctic retains the right to commercialize lecanemab in the Nordic region and is actively preparing for its launch in collaboration with Eisai. BioArctic incurs no development costs for lecanemab in Alzheimer’s disease and is entitled to payments upon achieving sales milestones, as well as royalties on global sales.
About BioArctic AB
BioArctic AB (publ) is a Swedish research-based biopharma company dedicated to pioneering treatments that can slow down or halt the progression of neurodegenerative diseases. The company is the originator of Leqembi® (lecanemab), the first drug demonstrated to slow disease progression and mitigate cognitive impairment in early Alzheimer’s disease. Leqembi was developed in partnership with Eisai, who manages regulatory affairs and global commercialization. In addition to Leqembi, BioArctic boasts a robust research pipeline featuring antibodies targeting Parkinson’s disease and ALS, along with additional Alzheimer’s disease projects. Several projects leverage the company’s proprietary BrainTransporter™ technology, which aims to actively transport antibodies across the blood-brain barrier to enhance treatment efficacy. BioArctic’s B share (BIOA B) is traded on Nasdaq Stockholm Large Cap. For more information, visit www.bioarctic.com.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
View original content:https://www.prnewswire.com/news-releases/sales-of-leqembi-totaled-23-1-billion-yen-in-the-second-quarter-2025–302518545.html
SOURCE BioArctic
“`
Original article, Author: Jam. If you wish to reprint this article, please indicate the source:https://aicnbc.com/6079.html
